Dov Elefant - 07 Nov 2025 Form 4 Insider Report for FEMASYS INC (FEMY)

Reporting relationship: Chief Financial Officer
Issuer ticker: FEMY
Reported as of: 07 Nov 2025
Net transaction value: +$25,000
SEC form: 4
Accepted by SEC: 12 Nov 2025, 17:23:57 UTC
Prior SEC filing: 28 Aug 2025
Next SEC filing: 20 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Kathy Lee-Sepsick, Attorney-in-fact

Key filing fact

Dov Elefant filed Form 4 for FEMASYS INC (FEMY) on 12 Nov 2025.

Key facts

This page summarizes Dov Elefant's Form 4 filing for FEMASYS INC (FEMY).
4 reported transactions and 4 derivative rows are listed below.
Accepted by SEC: 12 Nov 2025, 17:23.

Change

Previous filing in this sequence was filed on 28 Aug 2025.
Current net transaction value: +$25,000.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001326487 Primary reporting owner

Elefant Dov

Relationship: Chief Financial Officer
Address: C/O FEMASYS INC., 3950 JOHNS CREEK COURT, SUITE 100, SUWANEE
Signature: /s/ Kathy Lee-Sepsick, Attorney-in-fact
Signature date: 12 Nov 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

FEMY transaction Derivative

Senior Secured Convertible Notes

Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities

Transaction value: $25,000
Shares
Change %
Price
Shares after: $25,000
Date: 07 Nov 2025
Ownership: Direct
Underlying class: Common stock, par value $0.001 per share
Underlying amount: 34,122
Exercise price: $0.7300
Footnotes: F1, F5, F7

FEMY transaction Derivative

Series A-1 Warrants

Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities

Transaction value
Shares: +34,122
Change %
Price
Shares after: 34,122
Date: 07 Nov 2025
Ownership: Direct
Underlying class: Common stock, par value $0.001 per share
Underlying amount: 34,122
Exercise price: $0.8100
Footnotes: F2, F6, F7

FEMY transaction Derivative

Series B-1 Warrants

Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities

Transaction value
Shares: +34,122
Change %
Price
Shares after: 34,122
Date: 07 Nov 2025
Ownership: Direct
Underlying class: Common stock, par value $0.001 per share
Underlying amount: 34,122
Exercise price: $0.9200
Footnotes: F3, F6, F7

FEMY transaction Derivative

Series C-1 Warrants

Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities

Transaction value
Shares: +34,122
Change %
Price
Shares after: 34,122
Date: 07 Nov 2025
Ownership: Direct
Underlying class: Common stock, par value $0.001 per share
Underlying amount: 34,122
Exercise price: $1.10
Footnotes: F4, F6, F7

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 7 footnotes

Footnote F1

Holder may, at its option, prior to maturity, convert all or any portion of the outstanding amount of Senior Secured Convertible Notes due 2035 (the "Convertible Notes"), including accrued paid in-kind interest thereon, subject to certain limitations, into shares of Common Stock, at an initial conversion price of $0.73 per share of Common Stock. The conversion rate is subject to adjustment in accordance with the terms of the Convertible Notes and will be subject to standard adjustments in the event of any stock split, stock dividend, stock combination, recapitalization or other similar transactions.

Footnote F2

Holder may, at its option, exercise the Series A-1 Warrants, subject to the terms and conditions thereof, at an initial exercise price of $0.81 per share of Common Stock. The exercise price is subject to adjustment in accordance with the terms of the Series A-1 Warrants and will be subject to standard adjustments in the event of any stock split, stock dividend, stock combination, recapitalization or other similar transactions.

Footnote F3

Holder may, at its option, exercise the Series B-1 Warrants, subject to the terms and conditions thereof, at an initial exercise price of $0.92 per share of Common Stock. The exercise price is subject to adjustment in accordance with the terms of the Series B-1 Warrants and will be subject to standard adjustments in the event of any stock split, stock dividend, stock combination, recapitalization or other similar transactions.

Footnote F4

Holder may, at its option, exercise the Series C-1 Warrants, subject to the terms and conditions thereof, at an initial exercise price of $1.10 per share of Common Stock. The exercise price is subject to adjustment in accordance with the terms of the Series C-1 Warrants and will be subject to standard adjustments in the event of any stock split, stock dividend, stock combination, recapitalization or other similar transactions.

Footnote F5

Represents the maximum number of shares of Common Stock issuable upon the voluntary conversion of the original stated amount of the Convertible Notes. The number of shares issuable upon conversion of the Convertible Notes is subject to increase in connection with the accrual of interest, which is payable in kind. The Holder's ability to convert the Convertible Notes to shares of Common Stock is subject to certain limitations, in accordance with rules of the Nasdaq Capital Market.

Footnote F6

The Holder's ability to exercise the subject Warrant for shares of Common Stock is subject to certain limitations, in accordance with rules of the Nasdaq Capital Market.

Footnote F7

The reported securities were purchased by the reporting person for an aggregate amount of $25,000.